Article info

Download PDFPDF

1378 Preclinical characterization of IMGS-001, a dual antagonist anti-PD-L1, anti-PD-L2 antibody with effector function, to treat patients resistant to immune checkpoint blockade
Free

Authors

Citation

Salameh A, Pericle F, Gagliardi C, et al
1378 Preclinical characterization of IMGS-001, a dual antagonist anti-PD-L1, anti-PD-L2 antibody with effector function, to treat patients resistant to immune checkpoint blockade

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.